Keyword: Fluad

Seqirus expects to offer 50 million flu vaccine doses, while GSK plans to boost its supplies to 40 million to 45 million, its highest total ever.

Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.

Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly.

Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.

Seqirus has debuted its first commercial for Fluad, in an early flu season campaign targeting the 65-plus crowd.